<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424160</url>
  </required_header>
  <id_info>
    <org_study_id>KA20/23</org_study_id>
    <nct_id>NCT04424160</nct_id>
  </id_info>
  <brief_title>Effects of Platelet Rich Plasma on Endometrium</brief_title>
  <official_title>Effects of Intrauterine Platelet Rich Plasma (PRP) on Endometrium and Pregnancy Rates in Patients With Suboptimal Endometrium Undergoing Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal
      route after the cessation of menstrual period. The endometrial thickness will be assessed
      under ultrasound and hormone replacement will be started. As the endometrial thickness
      reaches adequate thickness during ultrasound follow-up, embryo transfer will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal
      route after the cessation of menstrual period. In the second menstrual period following the
      PRP injection, the endometrial thickness will be assessed under ultrasound and hormone
      replacement will be started. As the endometrial thickness reaches adequate thickness during
      ultrasound follow-up, embryo transfer will be performed. Pregnancy test results will be
      recorded and followed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal route after the cessation of menstrual period. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day. On the second menstrual cycle after the procedure, the patients will be checked under ultrasound and will be started hormone replacement therapy for embryo transfer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness during hormone replacement therapy</measure>
    <time_frame>2-10 months</time_frame>
    <description>To measure endometrial thickness assessed by ultrasound during hormone replacement therapy for endometrial preparation in frozen-thawed cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes after frozen-thawed embryo transfer</measure>
    <time_frame>2-10 months</time_frame>
    <description>To assess pregnancy rates by beta-human chorionic gonadotropin and ultrasound after frozen-thawed embryo transfer cycles</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Asherman Syndrome</condition>
  <arm_group>
    <arm_group_label>Endometrial PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in whom endometrial PRP was performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP injection in the endometrium</intervention_name>
    <description>Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.</description>
    <arm_group_label>Endometrial PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in whom cycle was cancelled due to an endometrial thickness &lt;7 mm when
             progesterone start was planned in patients undergoing frozen embryo transfer with
             hormone replacement therapy

          -  Women with a history of Asherman syndrome, but no obvious intrauterine adhesion in the
             last hysteroscopic procedure;

          -  Women who have at least 2 frozen good-quality embryos.

        Exclusion Criteria:

          -  Women with any other known cause of implantation failure, such as poor embryo quality,
             or congenital uterine anomalies, endometrial polyp or fibroid,

          -  Previous diagnosis of any malignancy,

          -  Anticoagulant use for which plasma infusion is contraindicated,
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All infertile women desiring pregnancy</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hulusi Bulent Zeyneloglu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University Departments of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
    <phone>+90-532-585 65 88</phone>
    <email>dryigit1@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bulent Tiras, Prof.</last_name>
    <phone>+90-533-290 37 17</phone>
    <email>bulent.tiras@acibadem.com.tr</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med. 2015 Jan 15;8(1):1286-90. eCollection 2015.</citation>
    <PMID>25785127</PMID>
  </results_reference>
  <results_reference>
    <citation>Tandulwadkar SR, Naralkar MV, Surana AD, Selvakarthick M, Kharat AH. Autologous Intrauterine Platelet-Rich Plasma Instillation for Suboptimal Endometrium in Frozen Embryo Transfer Cycles: A Pilot Study. J Hum Reprod Sci. 2017 Jul-Sep;10(3):208-212. doi: 10.4103/jhrs.JHRS_28_17.</citation>
    <PMID>29142450</PMID>
  </results_reference>
  <results_reference>
    <citation>Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. Treatment of thin endometrium with autologous platelet-rich plasma: a pilot study. JBRA Assist Reprod. 2017 Feb 1;21(1):54-56. doi: 10.5935/1518-0557.20170013.</citation>
    <PMID>28333034</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang Y, Li J, Wei LN, Pang J, Chen J, Liang X. Autologous platelet-rich plasma infusion improves clinical pregnancy rate in frozen embryo transfer cycles for women with thin endometrium. Medicine (Baltimore). 2019 Jan;98(3):e14062. doi: 10.1097/MD.0000000000014062.</citation>
    <PMID>30653117</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Bulent Tiras</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

